Drugs / GSK1034702
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00937846 | Jul → Aug 2009 | cognitive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00743405 | May → Dec 2008 | cognitive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01371799 Comparator | Dec 2009 → Jun 2010 | mental disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1034702 | “placebo, 4 and 8mg of GSK1034702” NCT01371799 ↗ |
| Action | Activate | “a potent muscarinic acetylcholine receptor type-1 (M1) allosteric agonist (GSK1034702)” PMID 26116126 ↗ Dec 2014 |
| Modality | Small molecule | — CHEMBL5095238 ↗ |
| Route | Oral | “single oral dose” NCT00743405 ↗ |